leisure time -WSS

leisure time

author：entertainment 2025-09-27 19:28:35 - browse：449

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

WSS

Telehealth for opioid use disorder is lifesaving

WATCH: Why do bright lights make us see spots?

Ohio still needs to do more to protect the right to abortion

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

FDA panel endorses Alnylam’s heart drug — after picking it apart

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

United colonoscopy coverage change 'may cost lives,' doctors say

New weight loss drugs vying to be the next Wegovy or Mounjaro

Dobbs anniversary: the lost opportunity of abortion as health care

Regeneron agrees to White House price limits on anti

Supreme Court strikes down use of affirmative action

Food makers tried to stack nutrition panel with preferred experts

Medicare proposal to cover medical devices draws a mixed reaction

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Apple is now the first public company to be valued at $3 trillion

A common UTI test for kids haunts adults as a traumatic 'nightmare'

knowledge

Food makers to regulators: Ultra

What is STAT's opinion section for?

White House drug czar issues call for 'recovery

How medical schools plan to diversify without affirmative action

How housing is health care on Long Island

Publishing genetic code of viruses could cause disaster

focus

hotspot

hotspot

entertainment